BRPI0717657A2 - Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii - Google Patents

Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii

Info

Publication number: BRPI0717657A2
Authority: BR; Brazil
Prior art keywords: compounds; dypythesia; diphypethydia; prophylaxy; obesity
Prior art date: 2006-10-19

Application number

BRPI0717657-0A2A

Other languages

English (en)

Inventor

Jean Ackermann

Kurt Amrein

Daniel Hunziker

Bernd Kuhn

Alexander V Wayweg

Werner Neidhart

Tadakatsu Takahashi

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-19

Filing date

2007-10-09

Publication date

2013-12-24

2007-10-09 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2013-12-24 Publication of BRPI0717657A2 publication Critical patent/BRPI0717657A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0717657-0A2A 2006-10-19 2007-10-09 Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii BRPI0717657A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06122591		2006-10-19
PCT/EP2007/060667 WO2008046758A2 (en)	2006-10-19	2007-10-09	Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes

Publications (1)

Publication Number	Publication Date
BRPI0717657A2 true BRPI0717657A2 (pt)	2013-12-24

Family

ID=39259578

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0717657-0A2A BRPI0717657A2 (pt)	2006-10-19	2007-10-09	Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii

Country Status (18)

Country	Link
US (1)	US8129423B2 (pt)
EP (2)	EP2104665A2 (pt)
JP (1)	JP5079011B2 (pt)
KR (2)	KR101118410B1 (pt)
CN (1)	CN101553474B (pt)
AR (1)	AR063332A1 (pt)
AU (1)	AU2007312391B2 (pt)
BR (1)	BRPI0717657A2 (pt)
CA (1)	CA2666489C (pt)
CL (1)	CL2007002972A1 (pt)
IL (1)	IL197955A0 (pt)
MX (1)	MX2009003939A (pt)
NO (1)	NO20091548L (pt)
PE (1)	PE20080890A1 (pt)
RU (1)	RU2439062C2 (pt)
TW (1)	TWI339120B (pt)
WO (1)	WO2008046758A2 (pt)
ZA (1)	ZA200902638B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2666762C (en)	2006-10-19	2014-12-30	F. Hoffmann-La Roche Ag	Aminomethyl-4-imidazoles
JP5079011B2 (ja)	2006-10-19	2012-11-21	エフ．ホフマン−ラロシュアーゲー	糖尿病のための１１β−ＨＳＤ１阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体
CA2678577A1 (en)	2007-02-26	2008-09-04	Vitae Pharmaceuticals, Inc.	Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
CL2008001839A1 (es)	2007-06-21	2009-01-16	Incyte Holdings Corp	Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009034062A1 (en) *	2007-09-11	2009-03-19	Glaxo Group Limited	Compounds which inhibit the glycine transporter and uses thereof in medicine
WO2009075835A1 (en)	2007-12-11	2009-06-18	Vitae Pharmaceutical, Inc	CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
US8124636B2 (en) *	2008-04-30	2012-02-28	Hoffmann-La Roche Inc.	Imidazolidinone derivatives as 11B-HSD1 inhibitors
NZ588954A (en) *	2008-05-01	2012-08-31	Vitae Pharmaceuticals Inc	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009134387A1 (en) *	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201004945A (en) *	2008-05-01	2010-02-01	Vitae Pharmaceuticals Inc	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2291373B1 (en) *	2008-05-01	2013-09-11	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MX2011000175A (es) *	2008-06-25	2011-06-27	Envivo Pharmaceuticals Inc	Compuestos heterociclicos 1,2-di-substituidos.
CN104327062A (zh) *	2008-07-25	2015-02-04	贝林格尔·英格海姆国际有限公司	11β-羟基类固醇脱氢酶1的环状抑制剂
TW201016691A (en)	2008-07-25	2010-05-01	Boehringer Ingelheim Int	Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2729993A1 (en)	2008-07-25	2010-01-28	Boehringer Ingelheim International Gmbh	Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
EP2393807B1 (en)	2009-02-04	2013-08-14	Boehringer Ingelheim International GmbH	Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
MA33216B1 (fr)	2009-04-30	2012-04-02	Boehringer Ingelheim Int	Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
WO2011011123A1 (en)	2009-06-11	2011-01-27	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2448928B1 (en) *	2009-07-01	2014-08-13	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2496589B1 (en)	2009-11-05	2014-03-05	Boehringer Ingelheim International GmbH	Novel chiral phosphorus ligands
TWI531571B (zh)	2009-11-06	2016-05-01	維它藥物公司	六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011149822A1 (en)	2010-05-26	2011-12-01	Boehringer Ingelheim International Gmbh	2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
JP5860042B2 (ja)	2010-06-16	2016-02-16	ヴァイティーファーマシューティカルズ，インコーポレイテッド	置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2585444B1 (en)	2010-06-25	2014-10-22	Boehringer Ingelheim International GmbH	Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EA201300522A1 (ru)	2010-11-02	2013-11-29	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтические комбинации для лечения метаболических нарушений
TWI537258B (zh)	2010-11-05	2016-06-11	百靈佳殷格翰國際股份有限公司	六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
CN102241678B (zh)	2011-04-26	2014-10-29	辽宁利锋科技开发有限公司	含有脂环结构化合物的抗肿瘤作用与应用
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013134079A1 (en)	2012-03-05	2013-09-12	Amgen Inc.	Oxazolidinone compounds and derivatives thereof
JP2015157764A (ja) *	2012-06-14	2015-09-03	大正製薬株式会社	グリシントランスポーター阻害物質
US9624214B2 (en)	2012-11-05	2017-04-18	Bayer Pharma Aktiengesellschaft	Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8796305B2 (en)	2012-11-05	2014-08-05	Bayer Pharma Aktiengesellschaft	Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en)	2012-11-05	2015-09-08	Bayer Pharma AG	Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en)	2012-11-05	2014-07-15	Bayer Pharma Aktiengesellschaft	Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
CN105339368B (zh)	2013-06-04	2017-08-15	拜耳制药股份公司	3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
WO2015018814A1 (de)	2013-08-08	2015-02-12	Bayer Pharma Aktiengesellschaft	Substituierte pyrazolo[1,5-a]pyridin-3-carboxamide und ihre verwendung
CN106459090A (zh)	2014-02-19	2017-02-22	拜耳制药股份公司	3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶
EP3119777A1 (de)	2014-03-21	2017-01-25	Bayer Pharma Aktiengesellschaft	Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
GB201416346D0 (en) *	2014-09-16	2014-10-29	Shire Internat Gmbh	Spirocyclic derivatives
EP3227286B1 (de)	2014-12-02	2018-12-26	Bayer Pharma Aktiengesellschaft	Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
CA2969268A1 (en)	2014-12-02	2016-06-09	Bayer Pharma Aktiengesellschaft	Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
JP2018505885A (ja)	2015-02-05	2018-03-01	バイエル・ファルマ・アクティエンゲゼルシャフト	置換ピラゾロ［１，５−ａ］−ピリジン−３−カルボキサミドおよびその使用
MX378995B (es)	2016-01-13	2025-03-11	Gruenenthal Gmbh	Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
LT3402782T (lt)	2016-01-13	2020-10-12	Grünenthal GmbH	8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
PL3722284T3 (pl)	2016-01-13	2025-03-31	Grünenthal GmbH	Pochodne 3-((hetero-)arylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
PL3402784T3 (pl)	2016-01-13	2020-09-21	Grünenthal GmbH	Pochodne 3-((hetero-)arylo)-alkilo-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekanu
MX379201B (es)	2016-01-13	2025-03-11	Gruenenthal Gmbh	Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
EP3235813A1 (en)	2016-04-19	2017-10-25	Cidqo 2012, S.L.	Aza-tetra-cyclo derivatives
RU2746423C2 (ru) *	2019-09-02	2021-04-13	Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар")	Ингибитор вируса гепатита В (ВГВ)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL24005A (en) *	1964-12-31	1970-05-21	Robins Co Inc A H	1,3-disubstituted-4-(2-substituted-ethyl)-2-imidazolidinones,processes for their production and pharmaceutical compositions containing them
GB1175820A (en)	1966-02-18	1969-12-23	Upjohn Co	Amino-Adamantane Derivatives
US3625956A (en) *	1967-12-08	1971-12-07	Ciba Geigy Corp	1-phenyl-4-alkyl-2-imidazolone derivatives
CH547288A (de) *	1971-06-23	1974-03-29	Ciba Geigy Ag	Verfahren zur herstellung neuer heterocyclischer stoffe.
GB9000725D0 (en)	1990-01-12	1990-03-14	Pfizer Ltd	Therapeutic agents
US5164403A (en)	1991-04-05	1992-11-17	G. D. Searle & Co.	N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5861420A (en) *	1991-04-05	1999-01-19	G. D. Searle & Co.	N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
TW218017B (pt) *	1992-04-28	1993-12-21	Takeda Pharm Industry Co Ltd
TR200101865T2 (tr) *	1998-12-24	2001-12-21	Fujisawa Pharmaceutical Co .Ltd.	İmidazol bileşimleri ve onların tıbbi kullanımları.
WO2002020493A2 (en) *	2000-09-06	2002-03-14	Chugai Seiyaku Kabushiki Kaisha	A traceless solid-phase synthesis of 2-imidazolones
CA2493458A1 (en) *	2002-07-24	2004-01-29	Ptc Therapeutics, Inc.	Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
PL1747198T3 (pl) *	2004-05-07	2008-11-28	Janssen Pharmaceutica Nv	Pochodne adamantylopirolidyn-2-onu jako inhibitory 11ß-dehydrogenazy hydroksysteroidowej
JP5137574B2 (ja) *	2004-08-30	2013-02-06	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	１１−ベータヒドロキシステロイドヒドロゲナーゼ阻害剤としての三環式ラクタム誘導体
CN103242192B (zh) *	2005-01-05	2016-05-04	Abbvie公司	11-β-羟甾类脱氢酶1型酶的抑制剂
JPWO2006104280A1 (ja) *	2005-03-31	2008-09-11	武田薬品工業株式会社	糖尿病の予防・治療剤
EP2311814A1 (en) *	2005-12-01	2011-04-20	F. Hoffmann-La Roche AG	2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents
DOP2007000015A (es)	2006-01-20	2007-08-31	Quark Biotech Inc	Usos terapéuticos de inhibidores de rtp801
JP2007254409A (ja) *	2006-03-24	2007-10-04	Taisho Pharmaceut Co Ltd	イミダゾリジノン誘導体
WO2008044656A1 (fr) *	2006-10-06	2008-04-17	Taisho Pharmaceutical Co., Ltd.	Dérivé d'imidazolidinone
WO2008046756A1 (en) *	2006-10-19	2008-04-24	F. Hoffmann-La Roche Ag	Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors
CA2666762C (en) *	2006-10-19	2014-12-30	F. Hoffmann-La Roche Ag	Aminomethyl-4-imidazoles
JP5079011B2 (ja)	2006-10-19	2012-11-21	エフ．ホフマン−ラロシュアーゲー	糖尿病のための１１β−ＨＳＤ１阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体
CL2007002994A1 (es)	2006-10-19	2008-02-08	Wyeth Corp	Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.

2007
- 2007-10-09 JP JP2009532768A patent/JP5079011B2/ja not_active Expired - Fee Related
- 2007-10-09 BR BRPI0717657-0A2A patent/BRPI0717657A2/pt not_active IP Right Cessation
- 2007-10-09 KR KR1020097007936A patent/KR101118410B1/ko not_active Expired - Fee Related
- 2007-10-09 RU RU2009118488/04A patent/RU2439062C2/ru not_active IP Right Cessation
- 2007-10-09 AU AU2007312391A patent/AU2007312391B2/en not_active Ceased
- 2007-10-09 EP EP07821040A patent/EP2104665A2/en not_active Withdrawn
- 2007-10-09 CN CN2007800387224A patent/CN101553474B/zh not_active Expired - Fee Related
- 2007-10-09 CA CA2666489A patent/CA2666489C/en not_active Expired - Fee Related
- 2007-10-09 WO PCT/EP2007/060667 patent/WO2008046758A2/en not_active Ceased
- 2007-10-09 KR KR1020117013229A patent/KR20110079776A/ko not_active Withdrawn
- 2007-10-09 EP EP10175995A patent/EP2308851A1/en not_active Withdrawn
- 2007-10-09 MX MX2009003939A patent/MX2009003939A/es not_active Application Discontinuation
- 2007-10-12 US US11/871,318 patent/US8129423B2/en not_active Expired - Fee Related
- 2007-10-16 TW TW096138731A patent/TWI339120B/zh not_active IP Right Cessation
- 2007-10-17 AR ARP070104597A patent/AR063332A1/es not_active Application Discontinuation
- 2007-10-17 PE PE2007001408A patent/PE20080890A1/es not_active Application Discontinuation
- 2007-10-17 CL CL200702972A patent/CL2007002972A1/es unknown
2009
- 2009-04-05 IL IL197955A patent/IL197955A0/en unknown
- 2009-04-16 ZA ZA200902638A patent/ZA200902638B/xx unknown
- 2009-04-20 NO NO20091548A patent/NO20091548L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA200902638B (en)	2010-03-31
AU2007312391B2 (en)	2012-06-21
CA2666489A1 (en)	2008-04-24
TW200831088A (en)	2008-08-01
RU2439062C2 (ru)	2012-01-10
KR20110079776A (ko)	2011-07-07
TWI339120B (en)	2011-03-21
US8129423B2 (en)	2012-03-06
WO2008046758A3 (en)	2009-06-11
PE20080890A1 (es)	2008-06-28
NO20091548L (no)	2009-05-05
MX2009003939A (es)	2009-05-11
KR20090065535A (ko)	2009-06-22
AR063332A1 (es)	2009-01-21
JP5079011B2 (ja)	2012-11-21
CA2666489C (en)	2012-10-02
KR101118410B1 (ko)	2012-04-23
RU2009118488A (ru)	2010-11-27
CL2007002972A1 (es)	2008-05-30
WO2008046758A2 (en)	2008-04-24
EP2104665A2 (en)	2009-09-30
EP2308851A1 (en)	2011-04-13
US20080103183A1 (en)	2008-05-01
JP2010506876A (ja)	2010-03-04
AU2007312391A1 (en)	2008-04-24
CN101553474B (zh)	2013-02-27
IL197955A0 (en)	2009-12-24
CN101553474A (zh)	2009-10-07

Legal Events

Date	Code	Title	Description
2015-08-11	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2016-04-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2327 DE 11-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0717657A2 (pt)	2013-12-24	Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii
BRPI0814825A2 (pt)	2015-02-03	Composto, processo para a preparação do composto, composição farmacêutica que o compreende, seu uso e métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação ou dislipimedia e diabetes do tipo ii
BRPI0811947A2 (pt)	2014-11-11	Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de obesidade, diabetes do tipo ii, dislipidemia ou síndrome metabólica
BRPI0818533A2 (pt)	2017-06-06	composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0715531A2 (pt)	2014-06-24	Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0816553A2 (pt)	2017-07-18	"composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BRPI0914927A2 (pt)	2017-06-20	composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BR122020011920A2 (pt)	2020-08-25	composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
CL2007003176A1 (es)	2008-07-25	Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI1009022A2 (pt)	2016-03-08	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
BR112012003464A2 (pt)	2015-09-08	composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
CL2007003423A1 (es)	2008-07-18	Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
BRPI0718586A2 (pt)	2014-03-11	Composto, processo para a sua preparação, composição farmacêutica contendo o mesmo, usos deste e método de tratamento ou prevenção de doenças
BRPI0907977A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
CL2008000887A1 (es)	2008-05-30	Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de
BRPI0815493A2 (pt)	2015-02-10	Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.
BRPI0924669A2 (pt)	2016-01-26	composto, uso de um composto, método para tratar a diabete melito e/ou obesidade, e, composição farmacêutica